Product Description
Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children. Diphenidol is a tertiary alcohol that is butan-1-ol substituted by two phenyl groups at position 1 and a piperidin-1-yl group at position 4. It has a role as an antiemetic. It is a member of piperidines, a tertiary alcohol and a member of benzenes. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Diphenidol)
Mechanisms of Action: mAChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Chile | China | Dominican Republic | Ecuador | Hong Kong | Mexico | New Zealand | Peru | South Africa | Taiwan | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Yabang Epson Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Dizziness|Motion Sickness
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20213278 | P1 |
Not yet recruiting |
Dizziness|Motion Sickness |
None |